Literature DB >> 7990118

7-azetidinylquinolones as antibacterial agents. 2. Synthesis and biological activity of 7-(2,3-disubstituted-1-azetidinyl)-4-oxoquinoline- and -1,8-naphthyridine-3-carboxylic acids. Properties and structure-activity relationships of quinolones with an azetidine moiety.

J Frigola1, A Torrens, J A Castrillo, J Mas, D Vañó, J M Berrocal, C Calvet, L Salgado, J Redondo, S García-Granda.   

Abstract

A series of 7-(2,3-disubstituted-1-azetidinyl)-1,4-dihydro-6-fluoro-4- oxoquinoline- and -1,8-naphthyridine-3-carboxylic acids, with varied substituents at the 1-, 5-, and 8-positions, was prepared to study the effects on potency and physicochemical properties of the substituent at position 2 of the azetidine moiety. The activity of the title compounds was determined in vitro against Gram-positive and Gram-negative bacteria, and the in vivo efficacy of selected derivatives was determined using a mouse infection model. The X-ray crystal structures of 6b, 6c, and 6d were found to be in reasonable agreement with the corresponding AM1 calculated geometries. Correlations between antibacterial potency of all the synthesized 7-azetidinylquinolones and naphthyridines and their calculated electronic properties and experimental capacity factors were established. Antibacterial efficacy and pharmacokinetic and physicochemical properties of selected derivatives were compared to the relevant 7-(3-amino-1-azetidinyl) and 7-(3-amino-3-methyl-1-azetidinyl) analogues (for Part 1, see: J. Med. Chem. 1993, 36, 801-810). A combination of a cyclopropyl or a substituted phenyl group at N-1 and a trans-3-amino-2-methyl-1-azetidinyl group at C-7 conferred the best overall antibacterial, pharmacokinetic, and physicochemical properties to the azetidinylquinolones studied.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7990118     DOI: 10.1021/jm00050a016

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Oxidative allene amination for the synthesis of azetidin-3-ones.

Authors:  Eileen G Burke; Jennifer M Schomaker
Journal:  Angew Chem Int Ed Engl       Date:  2015-08-19       Impact factor: 15.336

2.  Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.

Authors:  Meredith S Eno; Jason D Brubaker; John E Campbell; Chris De Savi; Timothy J Guzi; Brett D Williams; Douglas Wilson; Kevin Wilson; Natasja Brooijmans; Joseph Kim; Ayşegül Özen; Emanuele Perola; John Hsieh; Victoria Brown; Kristina Fetalvero; Andrew Garner; Zhuo Zhang; Faith Stevison; Rich Woessner; Jatinder Singh; Yoav Timsit; Caitlin Kinkema; Clare Medendorp; Christopher Lee; Faris Albayya; Alena Zalutskaya; Stefanie Schalm; Thomas A Dineen
Journal:  J Med Chem       Date:  2022-07-15       Impact factor: 8.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.